Cambridge University launches new initiative to support 'world-leading industry-academia collaborations' in therapeutics.
M2 PHARMA-March 9, 2017-Cambridge University launches new initiative to support 'world-leading industry-academia collaborations' in therapeutics
(C)2017 M2 COMMUNICATIONS
The University of Cambridge has launched a new initiative called the Cambridge Academy of Therapeutic Sciences (CATS), which is geared at creating a global, collaborative platform that unites academia and industry in the field of therapeutics. The scheme was inaugurated on Thursday by the vice-chancellor, the university announced.
CATS aims to "foster science that underpins the discovery of new treatments and diagnostics and the safe and effective use of existing medicines", while building upon Cambridge's reputation as a leader in academia. It hopes to create a dialogue across biological, physical, clinical and social sciences, as well as engineering. Moreover, it will have a clear relationship with industry.
The university noted that the arrival in Cambridge of major pharmaceutical companies AstraZeneca (LON: AZN) and Otsuka (Tokyo:4578), and the proximity of GSK (LON: GSK), mean the city is at the heart of commercial drug discovery in the UK and internationally.
Commenting on the news, Vice-Chancellor Professor Sir Leszek Borysiewicz said that he expected healthcare to entail the interplay of many industries, operators and individuals and to appear vastly different - in approach, therapies and patient care - in the coming years.
"There are few places in the world as well placed as the University of Cambridge to take advantage of this highly multidisciplinary scenario. The Cambridge Academy of Therapeutic Sciences will ensure that this capacity is fully exploited to speed up the development of new treatments that will benefit patients locally, nationally and internationally," he said.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 9, 2017|
|Previous Article:||BerGenBio ASA and Merck & Co. partner for phase II combination lung cancer trials.|
|Next Article:||The ICR calls on EMA to reform paediatric cancer trials regulations.|